{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:09:22Z","timestamp":1791223762874,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,9,20]],"date-time":"2014-09-20T00:00:00Z","timestamp":1411171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s00259-014-2896-2","type":"journal-article","created":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T13:00:54Z","timestamp":1411131654000},"page":"215-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["PET\/CT before autologous stem cell transplantation predicts outcome in refractory\/relapsed follicular lymphoma"],"prefix":"10.1007","volume":"42","author":[{"given":"Marion","family":"Alcantara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehan","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Mareschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S\u00e9gol\u00e8ne","family":"Cottereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Oberic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Meignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Ysebaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,20]]},"reference":[{"key":"2896_CR1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2008."},{"key":"2896_CR2","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2006-10-041863","volume":"109","author":"JG Gribben","year":"2007","unstructured":"Gribben JG. How I treat indolent lymphoma. Blood. 2007;109:4617\u201326.","journal-title":"Blood"},{"key":"2896_CR3","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","volume":"15","author":"P Brice","year":"1997","unstructured":"Brice P, Bastion Y, Lepage E, Brousse N, Ha\u00efoun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997;15:1110\u20137.","journal-title":"J Clin Oncol"},{"key":"2896_CR4","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725\u201332.","journal-title":"Blood"},{"key":"2896_CR5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42\u201351.","journal-title":"Lancet"},{"key":"2896_CR6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/annonc\/mdl014","volume":"17","author":"S W\u00f6hrer","year":"2006","unstructured":"W\u00f6hrer S, Jaeger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, et al. 18\u00a0F-fluoro-deoxy-glucose positron emission tomography (18\u00a0F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol. 2006;17:780\u20134.","journal-title":"Ann Oncol"},{"key":"2896_CR7","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","volume":"29","author":"J Trotman","year":"2011","unstructured":"Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29:3194\u2013200.","journal-title":"J Clin Oncol"},{"key":"2896_CR8","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/annonc\/mdt562","volume":"25","author":"S Luminari","year":"2014","unstructured":"Luminari S, Biasoli I, Versari A, Rattotti S, Bottelli C, Rusconi C, et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol. 2014;25:442\u20137.","journal-title":"Ann Oncol"},{"key":"2896_CR9","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014. doi: 10.1200\/JCO.2013.53.5229","journal-title":"J Clin Oncol"},{"key":"2896_CR10","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","volume":"30","author":"J Dupuis","year":"2012","unstructured":"Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS. J Clin Oncol. 2012;30:4317\u201322.","journal-title":"J Clin Oncol"},{"key":"2896_CR11","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/annonc\/mds657","volume":"24","author":"B Metzner","year":"2013","unstructured":"Metzner B, Pott C, M\u00fcller TH, Gebauer W, Casper J, Kraemer D, et al. Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation. Ann Oncol. 2013;24:1609\u201315.","journal-title":"Ann Oncol"},{"key":"2896_CR12","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1023\/A:1008399623564","volume":"11","author":"P Brice","year":"2000","unstructured":"Brice P, Simon D, Bouabdallah R, B\u00e9langer C, Ha\u00efoun C, Thieblemont C, et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol. 2000;11:1585\u201390.","journal-title":"Ann Oncol"},{"key":"2896_CR13","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003;21:3918\u201327.","journal-title":"J Clin Oncol"},{"key":"2896_CR14","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","volume":"26","author":"C Sebban","year":"2008","unstructured":"Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N, et al. Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol. 2008;26:3614\u201320.","journal-title":"J Clin Oncol"},{"key":"2896_CR15","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","volume":"96","author":"S Gouill Le","year":"2011","unstructured":"Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, et al. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study. Haematologica. 2011;96:1128\u201335.","journal-title":"Haematologica"},{"key":"2896_CR16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/asheducation.V2012.1.417.3798521","volume":"2012","author":"GG Laport","year":"2012","unstructured":"Laport GG. Changing role of stem cell transplantation in follicular lymphoma. Hematology Am Soc Hematol Educ Program. 2012;2012:417\u201325.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2896_CR17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.beha.2011.03.001","volume":"24","author":"E Bachy","year":"2011","unstructured":"Bachy E, Salles G. Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL. Best Pract Res Clin Haematol. 2011;24:257\u201370.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2896_CR18","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","volume":"98","author":"S Montoto","year":"2013","unstructured":"Montoto S, Corradini P, Dreyling M, Ghielmini M, Kimby E, L\u00f3pez-Guillermo A, et al. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica. 2013;98:1014\u201321.","journal-title":"Haematologica"},{"key":"2896_CR19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2011.03.007","volume":"11","author":"D Decaudin","year":"2011","unstructured":"Decaudin D, Mounier N, Tilly H, Ribrag V, Ghesqui\u00e8res H, Bouabdallah K, et al. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Clin Lymphoma Myeloma Leuk. 2011;11:212\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2896_CR20","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.","journal-title":"J Clin Oncol"},{"key":"2896_CR21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"2896_CR22","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50:1257\u201360.","journal-title":"Leuk. Lymphoma."},{"key":"2896_CR23","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2967\/jnumed.107.042093","volume":"48","author":"C Lin","year":"2007","unstructured":"Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626\u201332.","journal-title":"J Nucl Med"},{"key":"2896_CR24","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/0895-4356(95)00048-8","volume":"48","author":"P Peduzzi","year":"1995","unstructured":"Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48:1503\u201310.","journal-title":"J Clin Epidemiol"},{"key":"2896_CR25","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","volume":"116","author":"AJ Moskowitz","year":"2010","unstructured":"Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116:4934\u20137.","journal-title":"Blood."},{"key":"2896_CR26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","volume":"25","author":"ME Juweid","year":"2007","unstructured":"Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571\u20138.","journal-title":"J Clin Oncol"},{"key":"2896_CR27","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.3109\/10428194.2013.800201","volume":"54","author":"JF Seymour","year":"2013","unstructured":"Seymour JF, Trotman J, Hofman MS. Evaluating the place of FDG PET scanning in primary staging and beyond in patients with follicular lymphoma. Leuk Lymphoma. 2013;54:2093\u20135.","journal-title":"Leuk Lymphoma"},{"key":"2896_CR28","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","volume":"40","author":"E Itti","year":"2013","unstructured":"Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, V\u00e9ra P, et al. An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and \u0394SUVmax. Eur J Nucl Med Mol Imaging. 2013;40:1312\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2896_CR29","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.110.080556","volume":"51","author":"E Itti","year":"2010","unstructured":"Itti E, Juweid ME, Haioun C, Yeddes I, Hamza-Maaloul F, El Bez I, et al. Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med. 2010;51:1857\u201362.","journal-title":"J Nucl Med"},{"key":"2896_CR30","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/bjh.12741","volume":"164","author":"J Kothari","year":"2014","unstructured":"Kothari J, Peggs KS. Bird A, Thomson KJ, Morris E, Virchis AE, et al. Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure. Br J Haematol. 2014;164:334\u201340.","journal-title":"Br J Haematol"},{"key":"2896_CR31","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1002\/cncr.28243","volume":"119","author":"AM Evens","year":"2013","unstructured":"Evens AM, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS, et al. Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer. 2013;119:3662\u201371","journal-title":"Cancer"},{"key":"2896_CR32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2002-06-1793","volume":"101","author":"BD Cheson","year":"2003","unstructured":"Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood. 2003;101:391\u20138.","journal-title":"Blood."},{"key":"2896_CR33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","volume":"15","author":"JR Westin","year":"2014","unstructured":"Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15:69\u201377.","journal-title":"Lancet Oncol"},{"key":"2896_CR34","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","volume":"31","author":"R Pettengell","year":"2013","unstructured":"Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, et al. Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31:1624\u201330.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-014-2896-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-014-2896-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-014-2896-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T17:47:05Z","timestamp":1598291225000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-014-2896-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,20]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["2896"],"URL":"https:\/\/doi.org\/10.1007\/s00259-014-2896-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,20]]}}}